首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis
【24h】

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

机译:强烈免疫抑制,然后是自体血液杂化干细胞移植作为多发性硬化症的侵略性形式的治疗策略

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.
机译:在大多数重复多发性硬化症患者中,通过已经可用的批准疗法可以很容易地控制疾病。 然而,尽管治疗,存在一些侵略性的病例,其继续具有临床和磁共振成像(MRI)活性。 这些是现在可能从强烈免疫抑制中受益的病例,然后受到自体血液杂化干细胞移植(AHSCT)。 在本文中,我们描述了AHSCT的方法和基本原理,最近发表的研究表明其在选定的多发性硬化症病例中的疗效,与安全性有关的问题和程序的移植相关死亡风险。 概述了能够利用AHSCT的理想患者的描述,最后,简要介绍了靠近完成或接近开始的正在进行的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号